Gilgamesh Pharmaceuticals develops new chemical entities targeting the root causes of depression, anxiety, and stress-related disorders through advanced medicinal chemistry and an AI-powered discovery platform. Their therapies include rapid-acting, non-hallucinogenic neuroplastogens and safer ibogaine analogs, offering improved efficacy and safety profiles for patients.
Funding
$82.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Current treatments for depression, anxiety, and stress-related disorders often focus on symptom management rather than addressing the underlying neurological causes. Existing therapies may have slow onset, limited efficacy, or undesirable side effects, such as dissociative effects or cardiac safety concerns.
Solution
Gilgamesh Pharmaceuticals is developing a pipeline of novel, rapid-acting therapies that target the root causes of neurological diseases. Utilizing advanced medicinal chemistry and an AI-powered discovery platform, they are creating new chemical entities (NCEs) with improved efficacy and safety profiles. Their focus is on precision psychiatric therapies that move beyond symptom management to provide rapid-acting and long-lasting relief.
Target Audience
The primary target audience includes individuals suffering from depression, anxiety, stress-related disorders, and opioid use disorder, as well as healthcare providers seeking more effective and safer treatment options.
Features
- NMDAR Antagonists: Orally bioavailable, rapid-acting NCEs designed to minimize dissociative effects for the treatment of depression and other indications.
- 5-HT2AR Agonists: Rapid-acting antidepressant NCEs with optimized duration of effect and improved cardiac safety profiles for depression and other indications.
- Non-Hallucinogenic Neuroplastogens: Orally bioavailable, rapid-acting NCEs designed to be non-hallucinogenic for the treatment of depression and other indications.
- Safer Ibogaine Analogs: NCEs designed for rapid and sustained efficacy with an improved cardiac safety profile for opioid use disorder and other indications.
- AI-powered discovery and translational platform to accelerate the creation of novel precision psychiatric therapies.